CD8A and neoplasm: Intravenously administered VVL-m21 successfully remodeled the suppressive TME, increasing the numbers of effector CD8+ T cells within the tumor, enhancing levels of circulating natural killer (NK) cells and polarizing macrophages to an M1 phenotype.